You are here

  • Home
  • Archive
  • Volume 5, Issue 2
  • Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis

Citation Tools

Article menu

Download PDFPDF

Treatments
Original article
Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Glintborg B, Ibsen R, Bilbo REQ, et al
Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis
RMD Open 2019;5:e001016. doi: 10.1136/rmdopen-2019-001016